The medial preoptic area (MPOA), ventral pallidum (VP), and nucleus accumbens (NA) receive dopaminergic afferents and are involved in maternal behavior. Experiments investigated whether dopamine (DA) receptor antagonism in NA disrupts maternal behavior, determined the type of DA receptor involved, and investigated the involvement of drug spread to VP or MPOA. Injection of SCH 23390 (D1 DA receptor antagonist) into NA of postpartum rats disrupted retrieving at dosage levels that were ineffective when injected into MPOA or VP. Motor impairment was not the cause of the deficit. Injection of eticlopride (D2 DA receptor antagonist) into NA or VP was without effect. Results emphasize the importance of DA action on D1 receptors in NA for retrieval behavior.
The mesolimbic dopamine system is believed to play a significant role in the regulation of maternal responsiveness in rats: 6-hydroxydopamine lesions of either the ventral tegmental area (VTA) or nucleus accumbens (NA) disrupt maternal behavior (Hansen, Harthon, Wallin, Lofberg, & Svensson, 1991a , 1991b , and dopamine (DA) is released into NA when a postpartum rat interacts with pups (Champagne et al., 2004; Hansen, Bergvall, & Nyiredi, 1993) . If DA action on the NA is important for maternal behavior, a relevant question is the nature of the DA receptors that are involved. Keer and Stern (1999) reported that microinjection of flupenthixol, a mixed D1-D2 antagonist, into NA disrupts maternal behavior. Therefore, D1-like receptors, D2-like receptors, or both DA receptor types could be involved. Because increased c-fos expression occurs in the shell region of NA (NAs) during maternal behavior (Lonstein, Simmons, Swann, & Stern, 1998; Stack, Balakrishnan, Numan, & Numan, 2002) , and because DA acting on D1-like receptors can activate c-fos expression in NA (Blandini et al., 2003; Hunt & McGregor, 2002; Keefe & Gerfen, 1995; Moratalla, Xu, Tonegawa, & Graybiel, 1996) , it is possible that NA D1 receptors influence maternal behavior. In addition, a recent report found that the microinjection of pimozide, a D2 antagonist, into NA disrupted maternal behavior in rats (Silva, Bernardi, CruzCasallas, & Felicio, 2003) . There are two problems that hinder a proper interpretation of the results of the Silva et al. study. First, pimozide and control injections were not administered in a counterbalanced order. Second, pimozide may not be the best D2 antagonist to use, because it also blocks calcium channels independently of binding to D2 receptors (Santi et al., 2002) . Therefore, more exact work is needed to determine the involvement of NA D1-like and D2-like DA receptors in maternal behavior control.
VTA dopaminergic neurons project to other regions in addition to NA. There is a significant mesolimbic DA input to the ventral pallidum (VP; Klitenick, Deutch, Churchill, & Kalivas, 1992) , and DA action on VP has been shown to have significant behavioral and neurophysiological effects (Gong, Neill, & Justice, 1996 Maslowski-Cobuzzi & Napier, 1994) . Our laboratory has recently emphasized the importance of VP for maternal behavior: Excitotoxic lesions or microinjections of muscimol into VP severely disrupt maternal behavior in postpartum rats (Numan et al., 2005) . It is certainly possible that 6-hydroxydopamine lesions of the VTA or NA damaged DA input to VP, and that microinjection of DA antagonists into NA may have been effective because of spread to the nearby VP. For example, Keer and Stern (1999) disrupted maternal behavior by injecting 20 g of flupenthixol dissolved in 1 l of physiological saline into NA. It is highly likely that this dose-volume could have influenced VP. Of interest, because VP is a major target of NA GABAergic efferents (Robertson & Jian, 1995; Usuda, Tanaka, & Chiba, 1998; Zahm & Heimer, 1993) , one can conceive of a situation in which DA acts on one type of DA receptor in NA and another type in VP to influence maternal behavior.
Finally, the medial preoptic area (MPOA) is another brain region that is important for maternal behavior (Numan & Insel, 2003) , and there has been recent interest in the possible role of DA action on MPOA neurons in maternal behavior regulation (Lonstein, Dominguez, Putnam, De Vries, & Hull, 2003; Martin, LaPrairie, & Lonstein, 2004; Numan, 2004; Olazabal, Abercrombie, Rosenblatt, & Morrell, 2004) . Although MPOA does not get its DA input from VTA, but instead gets such input from diencephalic DA neurons (Simerly, Gorski, & Swanson, 1986; Wagner, Eaton, Moore, & Lookingland, 1995) , it is possible that 6-hydroxydopamine or DA receptor antagonist injection into NA affected maternal behavior, in part, because of the spread of the injected chemicals to MPOA. Most studies have used the dorsal striatum as an anatomical control for neurochemical manipulations applied to NA (Hansen et al., 1991a; Keer & Stern, 1999 ) and have not explored the possible involvement of MPOA or VP.
Our laboratory recently presented a neural model of the regulation of maternal behavior that includes interactions between MPOA, VTA, NA, and VP (Numan et al., 2005) . MPOA activation of mesolimbic DA release into NA is a critical component of the model. In order to begin to confirm aspects of this model, it would be important to show that manipulation of DA action in NA can affect maternal behavior and that such an effect can be shown to occur independent of an action on VP and/or MPOA neurons. Therefore, in a series of experiments, we injected relatively low doses (1, 2, or 3 g) of a standard D1-like DA receptor antagonist (SCH 23390) or a standard D2-like DA receptor antagonist (eticlopride) into either NA, VP, or MPOA and examined the effects of such injections on the maternal behavior of postpartum rats.
General Method

Subjects and Housing
The subjects were nulliparous female rats of the Charles River CD strain (Charles River, Wilmington, MA). At between 70 and 100 days of age, each female was bred with a male of the same strain. On the following morning, females were transferred to individual clear polycarbonate cages (20 ϫ 45 ϫ 20 cm) that contained wood shavings as bedding material. On Day 21 of pregnancy, females were transferred to clear polycarbonate observation cages (50 ϫ 40 ϫ 20 cm), which also contained wood shavings for bedding material. The floors of these observation cages were divided into four equal quadrants by 5-cm-high Plexiglas dividers. These barriers served to prevent pups from crawling from one quadrant to another. All subjects were maintained under a 12-hr reversed light-dark cycle (lights off at 0730), and food and water were freely available. During the dark phase, when behavioral observations occurred, test rooms were illuminated with dim red light.
Stereotaxic Surgery and Intracranial Injection Procedures
Stereotaxic surgery was carried out while the rats were under Nembutal anesthesia (50 mg/kg ip), which followed atropine sulfate pretreatment (0.2 mg/kg ip). Following surgery, females were injected with penicillin (50,000 units/kg sc) and were placed under a warming lamp to recover. Surgery was performed on Day 14 of pregnancy when bilateral 22-gauge stainless steel guide cannulas (Plastics One, Roanoke, VA) were implanted into either NA, VP, or MPOA. The DeGroot (1959) stereotaxic atlas was used for the NA and MPOA implants: Coordinates were (from interaural zero) A 9.5, L Ϯ 1.0, V 6.8 for the NA, and A 7.4, L Ϯ 1.0, V 5.8 for the MPOA. For the VP implants, the Paxinos and Watson (1986) atlas was used: Coordinates were (from interaural zero) A 8.7, L Ϯ 2.5, V 3.9. The implanted cannulas were occluded with stainless steel stylets that extended 2 mm beyond the end of the guide.
Females were bilaterally injected with various doses of DA antagonists. To perform the injections, the experimenter removed the inner stylet from the guide cannula of an awake hand-held rat and replaced it with a 28-gauge injector cannula that extended 2 mm beyond the end of the guide.
The injector cannula was attached to a Hamilton (Reno, Nevada) microliter syringe with polyethylene tubing, and the appropriate dose of the drug was injected into either NA, VP, or MPOA over a 60-s interval. The injector remained in place for another 45 s, at which time it was removed and the procedure was repeated on the other side of the brain.
Maternal Behavior a.m. Measurements and Observations
At about 1000 on each test day, the location of a female, pups, and nest were noted. On Day 1 postpartum, all litters were reduced to 6 pups and weighed; pups were selected randomly, but no direct attempt was made to equate the sex ratio. Maternal weights were also recorded. The pups were returned to the female (3 pups each to two quadrants outside the nest area), and a 15-min retrieval test was initiated. On Day 2 postpartum, a similar procedure occurred, except that each female first had the inner stylets of her bilateral guide cannula removed and reinserted. This procedure was performed in a room outside the maternal behavior testing room; the female was subsequently returned to the testing room, and a retrieval test began 20 min later. Only females that retrieved all of their pups to a common nest site within 15 min on both Days 1 and 2, and whose pups gained weight during this period, were retained in the study. Most females met this criterion, indicating that the implantation procedure and the stylet manipulation did not interfere with maternal behavior. The stylet manipulation was meant to adapt females to the intracranial injections that would occur on subsequent days in the same room. Females remained with their pups throughout the postpartum testing period, and litter and maternal weights were recorded daily.
Intracranial drug injections occurred on select postpartum days and on those days in which maternal behavior was measured, the following a.m. observations occurred over a 2-hr period beginning about 20 min after injection of the drug. Retrieval tests began with a 15-min continuous observation period. The latency to approach and sniff the pups and the occurrence of retrieval behavior were recorded. The location of the pups, the female, and the nest site was then noted at 30 min, 45 min, 60 min, and 120 min following the initiation of the retrieval test. If a female had not retrieved and grouped all of her pups to a common nest area by the end of this 2-hr period, the pups were returned to the female's original nest site as determined at the 1000 observation. Based on these observations, the following retrieval scores were assigned: All pups that were retrieved and grouped to a common site in 5 min ϭ 7, in 10 min ϭ 6, in 15 min ϭ 5, in 30 min ϭ 4, in 45 min ϭ 3, in 60 min ϭ 2, and in 120 min ϭ 1; not all pups retrieved and grouped to a common nest site within 120 min ϭ 0. In addition to these measures, we also recorded the number of pups that a female had retrieved (retrieval was defined as moving a pup from one quadrant to another) at each of the above observation points.
Each female's general activity was measured over the first 15 min after the introduction of pups into each female's cage. The absolute number of line crosses (movement of all four feet from one quadrant to another as defined by the Plexiglas dividers) was recorded. All line crosses were counted, including those that occurred during retrieval responses.
Nursing behavior was measured during the 45-to 60-min interval after the introduction of pups into each female's cage. A female was observed for about 10 -15 s every 30 s of the 15 min (a total of 30 observations), and it was noted whether she was hovering or crouching over her young. Usually a female engaged in only a single response during each observation interval. However, if a female transitioned from one behavior to another (hover to crouch, e.g.), the dominant behavior observed during the interval (in terms of duration) was recorded. One point was given for each positive observation. A female was recorded as nursing if she hovered or crouched over at least 2 pups (Stern & Johnson, 1990) . During hovering a female rests in an upright position, usually on her hind limbs, while the pups are under her ventral surface, and she is usually active, either sniffing and licking the pups or engaged in self-grooming. During crouching, also referred to as kyphosis, the female becomes quiescent and uses all four limbs to support a relatively immobile posture with her back either flat or slightly arched during a low crouch or intensely arched with legs rigid and splayed during a high crouch. In addition to these postures, a female can also nurse her young from a supine or prone position. In our observations, high and low crouches were designated as crouches, and hover, prone, or supine nursing was designated as a hover response. Prone and supine nursing were extremely rare, and the vast majority of our hover observations were in fact upright hover active nursing responses. We did not separately record instances of sniffing, licking, and grooming pups, although hovering behavior was typically associated with such activity in all of our groups.
Maternal Behavior p.m. Observations
At approximately 5 hr post intracranial injection, the location of each female and her pups was noted and a second 15-min nursing observation was taken. Following this observation, the pups were placed in two quadrants outside the nest area and a 15-min retrieval test occurred. The exact latency to retrieve all pups back to the nest site was recorded. These observations were taken to determine whether the effects of the drug had worn off and normal maternal responsiveness had resumed.
Histology
Females were perfused with saline followed by formaldehyde while under deep Nembutal anesthesia. Forty-m brain sections, cut on a freezing microtome, were stained with cresyl violet. Microscopic examination mapped the location of the cannula injection sites.
Statistics
For all analyses, a minimum significance level of p ϭ .05 (two-tailed test) was used. Ordinal scale data were analyzed with nonparametric statistics. When more than two independent groups were analyzed, the Kruskal-Wallis test was used first, and if an overall significant difference was detected, then Mann-Whitney U tests were performed for multiple comparisons. For dependent groups, we used the Friedman test followed by the Wilcoxon's test. Proportional data between independent groups were analyzed with the Fisher exact probability test. Correlations were analyzed with the Spearman rank correlation coefficient. Interval scale data were analyzed with analysis of variance (ANOVA), t tests, and the NewmanKeuls test. Interval scale data were analyzed with nonparametric statistics rather than ANOVA in cases in which there was a lack of homogeneity of variance across multiple groups.
Method for Experiment 1
This experiment, which used a 2 ϫ 3 experimental design, explored the effects of bilateral injections of various doses of R(ϩ)-SCH 23390 hydrochloride (a D1 DA receptor antagonist obtained from Sigma Chemical, St. Louis, MO) into either the medial NA (D1-NA; n ϭ 9) or VP (D1-VP; n ϭ 8) on ongoing maternal behavior. Within each independent group, a repeated measures design was used to examine the effects of various doses (0, 1, or 3 g/0.5 l per side, dissolved in sterile water) of the drug administered in a partially counterbalanced order on postpartum Days 3, 5, and 7. Maternal behavior observations did not occur on Days 4 and 6 postpartum; females remained with their pups, and maternal and pup weights were taken on these days and on Day 8 postpartum. The doses of SCH 23390 were in the range used by other investigators (Baldo, Sadeghian, Basso, & Kelley, 2002; Flores, Banoua, Galan-Rodriguez, & Fernandez-Espejo, 2004; Koch, Schmid, & Schnitzler, 2000; Nowend, Arizzi, Carlson, & Salamone, 2001; Sun & Rebec, 2005) .
Method for Experiment 2
This experiment, which used a 2 ϫ 3 experimental design, explored the effects of bilateral injections of various doses of S(Ϫ)-eticlopride hydrochloride (a D2 DA receptor antagonist obtained from Sigma Chemical) into either the medial NA (D2-NA; n ϭ 8) or VP (D2-VP; n ϭ 9) on ongoing maternal behavior. Within each independent group, a repeated measures design was used to examine the effects of various doses (0, 1, or 3 g/0.5 l per side, dissolved in sterile water) of the drug administered in a partially counterbalanced order on postpartum Days 3, 5, and 7. Maternal behavior observations did not occur on Days 4 and 6 postpartum; females remained with their pups, and maternal and pup weights were taken on these days and on Day 8 postpartum. The doses of eticlopride were in the range used by other investigators (Bernstein & Beninger, 2000; Flores et al., 2004; Gingrich, Liu, Cascio, Wang, & Insel, 2000; Kiyatkin & Rebec, 1999; Sun & Rebec, 2005) .
Method for Experiment 3
This experiment, which used a 2 ϫ 4 experimental design, explored the effects of bilateral injections of various doses of R(ϩ)-SCH 23390 hydrochloride into either the medial NA (D1-NA; n ϭ 8) or MPOA (D1-MPOA; n ϭ 7) on ongoing maternal behavior. Within each independent group, a repeated measures design was used to examine the effects of various doses (0, 1, 2, or 3 g/0.5 l per side, dissolved in sterile water) of the drug administered in a partially counterbalanced order on postpartum Days 3, 5, 7 and 9. Maternal behavior observations did not occur on Days 4, 6 and 8 postpartum; females remained with their pups, and maternal and pup weights were taken on these days and on Day 10 postpartum.
Method for Experiment 4
The purpose of this experiment was to get an independent measure of the effects of SCH 23390 on motor activity and maternal behavior. In Experiments 1 and 3, motor activity was measured in conjunction with maternal behavior. If a manipulation were to promote nursing behavior while depressing retrieval, this could indirectly affect our line cross measure of motor activity, and we would be unable to obtain a pure measure of the effect of the drug on general locomotor activity. Two independent groups were formed: The D1-NA group (n ϭ 8) received microinjections of SCH 23390 (2 g/0.5 l per side) into the medial NA on Days 3, 5, and 7 postpartum, whereas the sham group (SH-NA, n ϭ 8) received 0.5 l per side of sterile water into the medial NA. On Day 2, when the inner stylets were removed and reinserted to adapt females to the subsequent injections, a full 2-hr retrieving test was conducted. All rats in both groups showed normal retrieval behavior at this time, retrieving all their pups to the nest within 5 min. On Days 3 and 7, maternal behavior tests occurred as described for the previous experiments. On Day 5 a test for motor activity occurred. Twenty min following the intracranial injection, females were removed from their maternal behavior observation cages, put into a holding cage, and brought to another test room. Each female was placed into a clean maternal behavior observation cage that contained Plexiglas floor dividers. Food, water, and pups were not available. For a 5-min test period, the number of line crosses was recorded. Females were then returned to their home cages.
Results
Drug injections into certain brain regions had major effects on maternal behavior as measured during the a.m. observation period, and these results are described in the following sections for each experiment. However, these drug effects were reversible as measured at the p.m. observation period. In each of the four experiments, normal levels of retrieval behavior and nursing behavior were observed during the p.m. observation period (5 hr postinjection), and there were no significant differences across the various groups. In addition, all mothers maintained their body weights across the postpartum test period, all pups gained weight across test days, and there were no differences between the various groups on any of these measures. These results indicated that although the injection of certain DA antagonists into certain brain regions disrupted maternal behavior during the 2-hr a.m. observation period, this effect was not permanent and by 5 hr postintracranial injection, normal maternal behavior returned and the health and lactational proficiency of the injected females were not adversely affected.
Experiment 1
In this experiment, we examined the effects of bilateral injections of various doses of the D1 DA receptor antagonist SCH 23390 into either the medial NA or VP on postpartum maternal behavior. Figure 1 shows reconstructions of the location of the NA and VP injection sites, drawn onto the appropriate plates taken from the atlas of Paxinos and Watson (1997;  on the microtome, the brain sections for both groups were cut in the plane of this atlas). For the VP group, all of the bilateral injection sites were located within the VP, and they were concentrated at A 8.7-8.6 mm rostral to interaural zero. All of the NA injection sites were bilaterally located within the shell region of the rostral half of the NA (eight of nine sites were between A 10.6 and 11.2). Figure 2A shows the a.m. retrieval scores for the two groups across the various doses of SCH 23390. Retrieval did not vary across SCH 23390 doses in the VP group, and all females typically retrieved all pups to the nest site within 5 min. In contrast, the Friedman test indicated a significant difference in retrieving across SCH 23390 doses in the NA group. Wilcoxon's tests indicated that each dose of SCH 23390 in NA disrupted retrieval behavior in comparison to the 0-g injection. With respect to comparisons between the NA and VP groups, Mann-Whitney U tests indicated significantly lower retrieval scores in the NA group for the 1-(U ϭ 4.5, p Ͻ .002) and 3-g (U ϭ 2.5, p Ͻ .001) dose of SCH 23390. Of importance, the two groups did not differ at the 0-g dose. Females receiving the vehicle injection into NA typically retrieved all their pups to the nest site within 5 min, whereas retrieval was not completed for 1 to 2 hr in females receiving 1 and 3 g of SCH 23390 into NA. It is important to note that retrieval was not completely blocked as a result of SCH 23390 injections into NA. Instead, some pups would be retrieved and the female would begin nursing those pups, and then at various intervals she would leave the nest to retrieve another pup and resume nursing. Females receiving 1 g of SCH 23390 retrieved approximately 3 pups to the nest in the first 15 min of the retrieval test, whereas females receiving 3 g retrieved about 1 pup in 15 min. Forty-five min into the test, the mean number of pups retrieved was approximately 4 and 2, respectively. Figure 3 graphically depicts the cumulative mean number of pups retrieved over the 2-hr test period in the various groups. Figure 2B shows the data for the 15 min a.m. nursing observation that was taken at 45 to 60 min after pup presentation. A 2 ϫ 3 ANOVA (Injection Site ϫ SCH 23390 Dose, with repeated measures on the second factor) indicated no significant differences across doses in each group and across the NA and VP groups at each drug dose. Of course, although nursing duration did not differ between the NA and VP groups, at the 1-g and 3-g dose levels many of the NA females were nursing fewer pups because of the retrieval deficit (see Figure 3) . In Figure 2B , nursing duration includes all nursing responses, including both hovering and crouching. Table 1 shows a separate analysis for hover and crouching responses, and some group differences were detected. For hovering, a 2 ϫ 3 ANOVA indicated a significant interaction between implant site and drug dose, F(2, 30) ϭ 3.9, p ϭ .03. Subsequent analyses showed that the females that received 3 g of SCH 23390 into the NA showed more hover responses than females that received 0 g of the drug into NA or 3 g of the drug into VP. In other words, hovering responses were increased at the highest dose of SCH 23390 into NA. For crouch responses, ANOVA also revealed a significant interaction, F(2, 30) ϭ 3.5, p ϭ .04. Within the D1-NA group, females receiving 1 and 3 g of SCH 23390 showed fewer crouches than females receiving the 0-g dose, but Newman-Keuls comparisons indicated that only the comparison between the 0-and 1-g group reached statistical significance. Further analysis indicated that the crouch response level after the 1-g injection of the drug into NA was significantly lower than that observed in the corresponding VP group. The best summary of the data compiled in Figure 2B and Table 1 is that although overall nursing during the 15-min observation period was not disrupted after injection of SCH 23390 into NA, the type of nursing response displayed tended to be biased toward hovering and away from crouching. Table 2 shows the data on latencies to sniff pups and maternal activity levels (line crosses during the first 15 min after pup presentation) at the a.m. observation. All females in the NA and VP groups promptly approached and sniffed their pups within seconds of presentation, and within each group there were no differences across dose levels of SCH 23390. Of importance, at the 1-and 3-g dose levels, the NA females approached and contacted their pups as quickly as did the VP females. Of interest, the VP females had slightly shorter sniff latencies than the NA females at the 0-g dose level (U ϭ 17, p ϭ .05). With respect to line crosses, the NA females were less active than the VP females at the 1-(U ϭ 0, p Ͻ .001) and 3-g (U ϭ 10, p Ͻ .01) dose level of SCH 23390. Within the NA group, the 1-and 3-g doses significantly decreased activity when compared with the 0-g dose of SCH 23390. In the VP group, the 3-g dose of SCH 23390 significantly Figure 3 . Cumulative mean number of pups retrieved to the nest at different time points during a 2-hr retrieval test for females that received either 0 g (top), 1 g (middle), or 3 g (bottom) of the D1 dopamine receptor antagonist SCH 23390 into either the ventral pallidum (VP) or nucleus accumbens (NA).
decreased activity when compared with the 0-and 1-g doses. Of interest, within the D1-NA group, although retrieval scores were significantly correlated with line crosses at the 1-g dose of SCH 23390 (r ϭ .78, p ϭ .01), this was not the case for the 3-g dose of the D1 antagonist (r ϭ .02). Finally, we also measured line crosses at 45 to 60 min after pup presentation, at the time of the nursing observation (data not shown). At this time point, there were no differences between or within groups in general activity (even at the 3-g dose, where the NA females were still showing retrieving deficits): Activity levels were low in both groups at all doses because most females were quiescent and nursing pups.
In this experiment, we examined the effects of bilateral injections of various doses of the D2 DA receptor antagonist, eticlopride, into either the medial NA or VP on postpartum maternal behavior. Histological analysis of the injection sites indicated that the NA implants were in the shell region and that all VP implants were within the anatomical boundaries of the VP. The anteriorposterior locations of the NA and VP injection sites approximated those of the D1-NA and D1-VP sites of Experiment 1.
The behavioral results, which are shown in Table 3 , indicate that microinjection of 1 or 3 g of eticlopride into either the medial NA or VP did not disrupt maternal behavior or affect line cross activity. Significant differences were not detected within groups or between groups on any of the measures. When total nursing behavior was broken down into a separate analysis of hovering and crouching, again significant differences were not detected (data not shown). However, for retrieval behavior during the a.m. observation, it should be noted that there was a trend for the 3-g dose of eticlopride into NA to have a disruptive effect: Although 5/8 of these females retrieved all of their pups to the nest within 5 min, 2 of the remaining females did not retrieve all of their pups to the nest within the 2-hr observation period (retrieval score of 0), and a 3rd female completed retrieving her pups between 1 and 2 hr after pup presentation (retrieval score of 1).
Experiment 3
In this experiment, we examined the effects of bilateral injections of various doses of the D1 DA receptor antagonist SCH 23390 into either the medial NA or MPOA on postpartum maternal behavior. Figure 4 shows reconstructions of the location of the NA and MPOA injection sites, drawn on to the appropriate plates taken from the atlas of Paxinos and Watson (1997;  on the microtome, the brain sections for both groups were cut in the plane of this atlas). For the MPOA group, all of the bilateral injection sites were located within the caudal part of the MPOA and were concentrated at A 8.2 mm rostral to interaural zero. All of the NA injection sites were bilaterally located within the shell region or at the shell-core border of NA. The NA injection sites in this experiment were located slightly more caudally than those in Experiment 1: 6/8 sites in this experiment were located caudal to the A 10.6 plane. Figure 5A shows the a.m. retrieval scores for the two groups across the various doses of SCH 23390. The Friedman test indicated that retrieval did not vary across SCH 23390 doses in the MPOA group, but subsequent Wilcoxon's tests indicated that the lower retrieval score after 3 g into MPOA approached significance when compared with the 0-, 1-, and 2-g MPOA dose ( p Ͻ .07). Within the NA group, the Friedman test indicated that there was a significant difference in retrieving across SCH 23390 doses. Wilcoxon's tests indicated that each dose of SCH 23390 in NA disrupted retrieval behavior in comparison with the 0-g injection.
With respect to comparisons between the NA and MPOA groups, Mann-Whitney U tests indicated that the two groups did not differ at the 0-g dose but that the NA group had significantly lower retrieval scores than the MPOA group for the 1-(U ϭ 0, p Ͻ .001) and 2-g (U ϭ 5.5, p Ͻ .01) dose of SCH 23390. At the 3-g dose of the D1 antagonist, the NA and MPOA groups did not differ, although the lower retrieval score in the NA group approached significance (U ϭ 15.5, p Ͻ .12). Females receiving the vehicle injection into NA typically retrieved all their pups to the nest site within 5 min, whereas retrieval was not completed for 30 to 45 min in females receiving 1-and 2-g of SCH 23390 into NA and for about 1 hr for females receiving the 3-g dose. It is important to note that retrieval was not completely blocked as a result of SCH 23390 injections into NA. As in Experiment 1, some pups would be retrieved and the female would begin nursing those pups, and at various intervals she would leave the nest to retrieve another pup and then resume nursing. Females in the MPOA groups that received 0, 1, or 2 g of SCH 23390 typically retrieved all their pups to the nest in 5 min. With respect to the retrieval deficit in the 3-g MPOA group, some females retrieved only part of their litter to the nest in the early part of the retrieval test. Therefore, the nature of the deficit, although less extreme, was not different from that observed in the NA group. More information on a comparison of retrieval behavior in the 3-g NA and MPOA groups is shown in Figure 6 . Of importance, t tests indicated that the cumulative mean number of pups retrieved by the NA group was significantly lower than that of the MPOA group when analyzed through the 45-min interval of the retrieval test. Therefore, although the overall difference in retrieval latencies between the 3-g MPOA and NA groups did not reach statistical significance, these results clearly show the inferior retrieval behavior of the NA-injected females.
Figure 5B shows the data for the 15-min a.m. nursing observation that was taken at 45 to 60 min after pup presentation. Because the variances were not equal, we used nonparametric statistics.
Within the NA and MPOA groups, nursing did not differ significantly across doses of SCH 23390. Mann-Whitney comparisons between the NA and MPOA groups indicated that differences did not exist at the 0-, 1-, and 2-g dose levels. At the 3-g dose level of the D1 antagonist, the NA females showed less nursing behavior (U ϭ 12, p Ͻ .05). When a separate analysis was performed on hovering and crouching, no differences between any of the groups were detected for hovering behavior. However, statistical (t test) analysis did indicate that the 3-g NA group had a significantly lower mean crouch score (15.50 Ϯ 3.60) than did the 3-g MPOA group (26.14 Ϯ 1.98), while no other differences were significant (these results were analyzed with parametric statistics because variances did not differ). Table 4 shows the data on latencies to sniff pups at the a.m. observation and on maternal activity levels (line crosses during the first 15 min after pup presentation at the a.m. observation). Most females in both the NA and MPOA implant groups promptly approached and contacted their pups, and Mann-Whitney U tests indicated that there were no differences between these groups at all dose levels of SCH 23390. However, the Friedman test indicated that sniff latencies differed significantly across doses of the D1 antagonist in the NA group, and Wilcoxon's tests showed that females receiving either 2 or 3 g of SCH 23390 into NA had slightly but significantly longer sniff latencies than did females in the 0-g NA dose group. In the MPOA group, the Wilcoxon's test also indicated that the sniff latency difference between the 0-g and 3-g dose level approached significance ( p Ͻ .06).
With respect to the line cross activity data, a 2 ϫ 4 ANOVA (Injection Site ϫ SCH 23390 Dose, with repeated measures on the second factor) indicated a significant effect of injection site, F(1, 13) ϭ 17.16, p ϭ .001, and SCH 23390 dose, F(3, 39) ϭ 12.84, p Ͻ .0001, and an interaction that approached significance, F(3, 39) ϭ 2.74, p ϭ .0562. Subsequent analyses indicated that whereas line crosses did not vary across doses of SCH 23390 in the MPOA group, activity did vary across drug doses in the NA group, F(3, 21) ϭ 17.48, p Ͻ .0001, with the 1-, 2-, and 3-g dose groups displaying less activity than the 0-g group, and with the 3-g group being less active than the 1-and 2-g groups. Finally, the D1-NA females showed less activity than the D1-MPOA females at the 2-(t test, p ϭ .01), and 3-g (t test, p ϭ .001) doses of SCH 23390, but the groups did not differ at the 0-and 1-g dose (at 1 g, the difference between the groups approached significance, p Ͻ .10). It is worth noting that the activity effects of the 1-and 2-g doses of SCH 23390 into NA were relatively modest (see Table 4 ). Of importance, the Spearman rank correlation coefficient indicated that line cross activity and retrieval score were not positively correlated in the NA group for each dose of SCH 23390, although the correlation approached significance at the 1-and 2-g doses (r ϭ .66, p Ͻ .10).
Experiment 4
In this experiment, we examined the effects of the injection of either 2 g of SCH 23390 (D1-NA group) or sterile water (sham procedure ϭ SH-NA group) into the medial NA on maternal behavior and general locomotor activity. On Days 3 and 7 postpartum, maternal behavior and lines crosses were measured as Figure 6 . Cumulative mean (Ϯ SE) number of pups retrieved to the nest at different time points during a 2-hr retrieval test for females that received 3 g of the D1 dopamine receptor antagonist SCH 23390 into either the medial preoptic area (MPOA) or nucleus accumbens (NA). Asterisks indicate a significant difference (as revealed by a t test) from the corresponding MPOA group. Note. Interquartile ranges are shown in parentheses. D1 refers to SCH 23390, a D1 dopamine receptor antagonist. Means in the same column that do not share the same subscripts differ significantly in a t test ( ps Ͻ .05). previously described. On Day 5, line crosses were measured over a 5-min period in a novel cage in which pups were not present.
Table 4 Outcome Measures in Postpartum Rats That Received Various Doses of SCH 23390 into Either the Medial Preoptic Area (MPOA) or Nucleus Accumbens (NA)
Histological analysis indicated that all of the bilateral injection sites in both groups were appropriately located in the medial part of NA. Of importance, 6/8 D1-NA injection sites were located in the rostral NA (between A 10.6 and 11.2). Table 5 shows the maternal behavior results as recorded on Days 3 and 7 postpartum. Similar to the previous findings, SCH 23390 injections into NA disrupted retrieval behavior on both Days 3 (U ϭ 4, p ϭ .002) and 7 (U ϭ 4, p ϭ .002) when compared with the corresponding SH-NA group. Sham females typically retrieved all their pups to the nest within 5 min, whereas the D1-NA females initially retrieved only part of their litter, periodically leaving the nest over subsequent time points to retrieve additional pups. This behavior resulted in median latencies of 1 to 2 hr to complete retrieval. In contrast to retrieval behavior, nursing behavior was not affected by the SCH 23390 injections, although such females were nursing fewer pups. A separate statistical analysis of hovering and crouching behavior also did not detect any group differences (data not shown). Finally, although the D1-NA females showed retrieval deficits, they all promptly approached and sniffed their pups within a matter of seconds at the beginning of each retrieval test. Table 6 shows the activity data. On Days 3 and 7, line cross activity was measured over the first 15 min after pup presentation, and the D1-NA females showed significantly lower activity than did the SH-NA females on each day (t test, p Ͻ .0001). A possible reason for this effect was that whereas SH-NA females were retrieving all of the pups (which requires line cross activity), the D1-NA females tended to only retrieve a few pups in the first 15 min, spending most of their time engaging in stationary nursing behavior. On Day 5, therefore, we tested activity over only a 5-min period in a novel cage that did not contain food, water, or pups. In this situation, the SH-NA females were still more active than were the D1-NA females (t test, p ϭ .002). Of importance, however, subsequent correlated t tests within each group showed that the D1-NA females were significantly more active on Day 5 when compared with either Day 3 or Day 7 ( p Յ .01), which was not the case for the SH-NA females. It is also worth pointing out that the mean number of line crosses observed for the D1-NA group in the novel cage situation on Day 5 (18.25) did not differ significantly (as measured by t tests) from the number of line crosses shown over the first 15 min after pup presentation that was recorded for females that received either 3 g of SCH 23390 into VP (Experiment 1, M ϭ 19.5), or 1 or 2 g of SCH 23390 into MPOA (Experiment 3, M ϭ 22.71 for both groups). Although it is not appropriate to make comparisons across experiments, these results strongly suggest that the females that received 2 g of SCH 23390 into NA in Experiment 4 were capable of activity levels that would have allowed them to retrieve all their pups to the nest within 5 min, and yet they showed severe retrieval deficits on both Days 3 and 7 of testing.
Discussion
The results of this study provide strong evidence that blockade of DA action on D1-like receptors in the shell region of NA disrupts retrieval behavior in postpartum rats. The 1-and 2-g doses of SCH 23390, a selective DA receptor antagonist for the D1-D5 receptor class (Missale, Nash, Robinson, Jaber, & Caron, 1998) , disrupted retrieval behavior when injected into NAs but did not disupt such behavior when injected into VP or MPOA. The 3-g dose of the drug caused a major disruption of retrieval behavior when injected into NAs, a mild disruption of retrieval when injected into the MPOA, and no effect on retrieval when injected into VP. These results are extremely important from a localization of function point of view because the MPOA, VP, and NA are anatomically close to one another, all are involved in maternal behavior (Numan et al., 2005) , and all receive some DA input (see references cited in the Introduction). By showing that certain doses of SCH 23390 are effective in the NAs, but have no effect on VP and MPOA, we rule out the possibility that the disruptive effect of NAs injections of SCH 23390 on retrieving was due to spread to these other regions. These findings do not mean that DA action on D1 receptors in MPOA or VP is not involved in maternal behavior because other evidence (Martin et al., 2004 ; current study) suggests that higher doses might be effective, particularly in MPOA. However, our results strongly show that the disruption of retrieval by relatively low doses of SCH 23390 into NAs is a local effect and not due to spread to nearby "maternally relevant" regions that also receive DA input. The fact that D1 receptors in NA are involved in maternal behavior is important because fos expression in NAs is increased during maternal behavior, and DA action on D1 receptors is capable of activating fos expression in NA (Hunt & McGregor, 2002; Moratalla et al., 1996) . D1 antagonism in NA disrupted retrieval behavior, but, for the most part, did not disrupt total nursing duration. This finding suggests that DA action on D1 receptors in NAs is most important for proactive voluntary maternal responses like retrieval behavior but is not necessary for the more reflexive responses involved in nursing behavior (Keer & Stern, 1999; Numan & Insel, 2003) . As is developed subsequently in this article, MPOA lesions have a similar disruptive effect on maternal behavior (Numan & Insel, 2003) , suggesting an interaction between MPOA and NAs DA levels in the control of maternal retrieving. Other researchers have also shown that disruption of DA input to the NA does not grossly interfere with nursing behavior (Hansen et al., 1991a (Hansen et al., , 1991b Keer & Stern, 1999) . We should note that Hansen et al. performed brief nursing observations, and our nursing observations were only 15 min long. Therefore, we do not rule out the possibility that more extensive observations of nursing would have detected more profound effects than we detected in the current study. Of interest, Keer and Stern did take more extensive observations of nursing behavior after microinjection of flupenthixol (a mixed D1-D2 antagonist) into the NA, and they found that such injections decreased hovering behavior and increased the duration of kyphosis. This finding contrasts with ours. When we analyzed hovering and crouching separately, we found a tendency toward an increase in hovering and a decrease in crouching after SCH 23390 injections into NA. This difference is likely due to methodological differences between the two studies. Keer and Stern were more interested in detecting effects on nursing behavior, and we were more interested in detecting differences in retrieval behavior (because of the possible functional link between the MPOA and NA in the regulation of retrieval). Therefore, Keer and Stern only studied retrieval behavior for 5 min, and if a female did not retrieve during this interval, the experimenters then placed all the pups in the female's nest and examined nursing for 30 min. Because the duration of drug action is limited, one has to choose the behavior to concentrate on, and we chose to give a 2-hr retrieval test with a 15-min nursing observation from 45 to 60 min after pup presentation. However, at this time point, many of the females in the D1-NA groups had not yet completed retrieval. Because the number of pups suckling is positively related to the incidence of kyphosis (Stern & Johnson, 1990) , it is likely that we observed more hovering and less crouching in some of our groups because fewer pups were suckling.
An important aspect of maternal behavior that was not quantified in the current study was the dam's licking and grooming of her pups. This behavior plays an important role in regulating aspects of infant development, and relatively subtle variations in licking and grooming can have dramatic effects on such development (Boccia & Pedersen, 2001; Caldji et al., 1998; Pedersen & Boccia, 2003) . Although we did not quantify maternal licking and grooming, our qualitative observations indicated that females that received SCH 23390 into NA did engage in such behavior while hovering over their pups. However, we are not in a position to determine whether such behavior was significantly reduced by the injection of the D1 antagonist into NA. Our prediction is that we would have found a significant reduction if we had performed a quantitative analysis because (a) Keer and Stern (1999) reported that flupenthixol injections into NA depressed licking and grooming of pups, and (b) Champagne et al. (2004) found that the amount of DA released into NA is positively correlated with the degree of the dam's licking and grooming of her pups, and females that licked and groomed their pups at a high level also had increased D1 receptors in NAs.
Using microinjections of eticlopride, a selective antagonist for the D2 class of DA receptors (D2-D3-D4; Missale et al., 1998) , at dosage levels that others have found to be behaviorally effective (Boye, Grant, & Clarke, 2001; Sun & Rebec, 2005) , we did not detect any disruptive effects on maternal behavior after injections into NA or VP. Although the molecular weight of eticlopride is slightly larger than that of SCH 23390, the minor difference in the administered molar doses of the two drugs cannot explain the results we obtained, as the administration of eticlopride at 3 times the effective dose of SCH 23390 did not significantly disrupt maternal behavior. However, our reported results do suggest that eticlopride doses higher than 3 g might have been effective in the NA. Although eticlopride's effectiveness in blocking D2 receptors appears to equal the effectiveness of SCH 23390 in blocking D1 receptors (Missale et al., 1998) , some behavioral studies suggest that higher doses of eticlopride might be necessary to produce the same behavioral effects as lower doses of SCH 23390 (Fowler & Liou, 1998) . Therefore, we are not ruling out the possibility that DA action on both D1-and D2-like receptors in NA might act together to influence maternal behavior (see Ikemoto, Glazier, Murphy, & McBride, 1997) . In addition, a more fine-grained analysis of maternal behavior than that performed in the current study might have detected effects on maternal behavior from the doses of eticlopride that we administered. Finally, because we did not inject eticlopride into MPOA, we cannot speak to its action at that site. However, the combined results of the SCH 23390 and eticlopride experiments provide evidence for both the anatomical and chemical specificity of our findings: Relatively low doses of a D1 antagonist appear to act on the NAs to disrupt retrieval behavior.
It is interesting to note that SCH 23390 appeared to have a greater disruptive effect on maternal retrieving in Experiments 1 and 4 than in Experiment 3. The NA implant sites in the third experiment were located more caudally than in the other two, implicating the importance of DA-D1 interaction in the rostral NAs for the regulation of maternal retrieving.
What is the mechanism through which D1 antagonism in NAs disrupts maternal retrieval behavior? One possibility is that the deficit was simply the result of a motor incapacitation. D1 antagonism in NAs did decrease general locomotor activity as measured by line crosses across the different quadrants of the test cage, and this disruption occurred whether pups were in the cage, which allowed the females to engage in motorically inactive nursing behavior, or whether the females were tested in a novel cage without the pups. However, the following findings tend to rule out such a simple explanation. First, females that received SCH 23390 injections into NAs typically approached and sniffed their pups as quickly as did control females (or nearly as quickly). Second, in Experiment 3, although the 1-g dose of SCH 23390 disrupted retrieval behavior in the NA group, but not in the MPOA group, the number of line crosses shown by the NA females was not significantly lower than that shown by the MPOA females. Third, although the latency to retrieve all pups to the nest was dramatically increased after SCH 23390 injections into NAs, some pups were retrieved at various intervals after the drug injection, indicating that the retrieval response could be performed throughout the 2-hr test. Fourth, females receiving SCH 23390 into NAs were not inactive, indicating that they were capable of voluntary line crosses. Fifth, in females injected with 2 g of SCH 23390 into NAs, activity levels were higher when they were tested without pups in a novel cage over a 5-min period compared with when they were tested with their pups in their home cages over a 15-min period, suggesting that engaging in nursing activity played some role in the lower activity levels of females with pups. In other words, it appears that the females could have left the nest to complete the retrieval of their pups but tended to engage in nursing behavior instead. Indeed, the activity level shown over 5 min in the novel cage by females receiving 2 g of SCH 23390 into NA approximated the 15-min activity levels of females that received 3 g of the drug into VP or 1 or 2 g of the drug into the MPOA, and the females in these latter 3 groups typically retrieved their pups to the nest in 5 min. Sixth, in the present experiments, measures of maternal behavior and activity began 20 min post drug injection. It could be argued that the full effect of the SCH 23390 injection into NAs may not have fully manifested itself until a later time point. This possibility has been ruled out by unpublished findings from our lab. When we delayed the onset of the testing regimen until 35 min postinjection, we observed the same basic results: Sniff latencies were not affected; some, but not all, pups were retrieved; and activity levels were the same as when measured 20 min postinjection.
We share the view of many other investigators that DA action in the NA is involved in regulating or modulating the behavioral reactivity of an organism to motivationally significant stimuli. More specifically, the mesolimbic DA system, which originates in the VTA and terminates, in part, in NA, has long been considered a critical component of a neural system involved in motivated or goal-directed behavior (Berridge & Robinson, 1998; Blackburn, Pfaus, & Phillips, 1992; Horvitz, 2002; Ikemoto & Panksepp, 1999; Mogenson, 1987; Salamone & Correa, 2002) . The idea is that DA action at the level of the NA plays a role in gating the access of biologically significant sensory stimuli to other parts of the brain where such stimuli can be processed so that adaptive behavioral responses can occur (Yun, Nicola, & Fields, 2004) . According to this view, DA antagonism at the level of NA should decrease the effectiveness of pup stimuli to evoke proactive voluntary retrieval responses. It should be noted, however, that the mesolimbic DA system is a nonspecific system involved in the control of a variety of motivated behaviors, which includes an involvement in ingestive behavior (Zhang, Balmadrid, & Kelley, 2003) , male sexual behavior (Everitt, 1990; Pfaus & Phillips, 1991) , female sexual behavior (Becker, Rudnick, & Jenkins, 2001) , and maternal behavior (see references cited in the Introduction to this article). Therefore, it should not be surprising that DA antagonism at the level of NA not only should decrease behavioral reactivity to pups located outside the nest but also should decrease the behavioral arousing effects of a novel test cage.
If the mesolimbic DA system is a nonspecific system, how do we get behavioral specificity? Why does a postpartum female retrieve pups,whereas a naive virgin female rat does not (Numan & Insel, 2003) ? We have proposed that behavioral specificity occurs because specific behavioral systems regulate the activity of the nonspecific mesolimbic DA system, in this way determining the particular stimuli to which the organism responds. Neurons within the MPOA appear to be specifically related to maternal responsiveness, and we have argued that in postpartum females MPOA efferents activate VTA neurons under particular stimulus conditions, causing the release of DA into NA, and that DA then acts to promote proactive voluntary maternal responses to pup stimuli (Numan, 1985; Numan & Insel, 2003; Numan & Numan, 1997) . Naive virgin females do not retrieve pups because it is presumed that the MPOA does not activate the VTA in these females. In partial support of these ideas, Numan and Smith (1984) found that when a unilateral MPOA lesion is paired with a contralateral VTA lesion, a relatively specific deficit in maternal retrieving is observed. In addition, Stack et al. (2002) found that a unilateral lesion of MPOA, which does not disrupt maternal behavior (bilateral lesions are necessary), disrupted maternal-behavior-induced fos expression in the ipsilateral, but not the contralateral, NAs.
How does DA perform its gating functions in the NA? This question is very controversial, and research findings have presented conflicting answers (Pennartz, Groenewegen, & Lopes Da Silva, 1994) . The NA receives excitatory glutamate input from the prefrontal cortex (PFC), amygdala, and hippocampus (Pennartz et al., 1994) . The major output neurons of the NA are GABAergic, and one site to which they project is the VP (Pennartz et al., 1994) . On the basis of many elegant experiments, Mogenson (1987) suggested that DA acts to inhibit excitatory transmission in NA and that this effect releases the VP from inhibition by NA efferents. Activity in VP then promotes behavioral activity. In other words, suppression of NA output was viewed as essential for behavioral reactivity. In contrast, others have suggested that NA output is necessary for selective behavioral reactivity and that DA functions in the NA to inhibit weak excitatory inputs from the PFC and limbic system (amygdala and hippocampus) while potentiating the effects of strong excitatory inputs (Horvitz, 2002; Nicola, Surmeier, & Malenka, 2000) . This effect would allow only strong sensory inputs to the NA to drive its output, and then this GABAergic output to the VP and to other sites would allow behavioral responsiveness to selectively occur to strong stimulus inputs. The major difference between these two views is that Mogenson suggested that VP activity is necessary for behavioral reactivity, whereas the more recent views imply that VP inhibition is necessary for behavioral reactivity.
We recently published a study that is more consistent with Mogenson's (1987) views (Numan et al., 2005) . We found that NA lesions did not disrupt maternal behavior in postpartum rats, whereas VP lesions did. In addition, muscimol (a GABA agonist) injections into VP disrupted maternal behavior, whereas NA muscimol injections were ineffective. These results are consistent with Mogenson's view that depression of NA activity and activation of VP are necessary for goal-directed behavior to occur. Numan et al. also found that females that sustained cell body lesions of the MPOA on one side of the brain and cell body lesions of VP on the other side of the brain showed a specific deficit in retrieval behavior while showing normal levels of general locomotor activity and normal hoarding behavior.
On the basis of those findings and the findings of the present experiment, we want to build on Mogenson's model to present a novel model of the neural regulation of maternal behavior (see Yun et al., 2004 , for a possible alternative model), which is depicted in Figure 7 . When appropriately primed by hormones, the MPOA responds to pup stimuli and sends out efferent projections to the VTA, which activate DA release into NA. We propose that DA action on D1 receptors inhibits NA, in this way releasing the VP from inhibitory NA control. Also note that external stimuli, including pup stimuli, are shown as activating both NA and VP. This is a crucial aspect of the model. If MPOA were not active, as in nonmaternal females, these two forces would oppose one another and VP would not show a strong response to pup stimulation. However, when MPOA is active, it inhibits the response of NA to pup stimuli via activation of DA input to NA, and this promotes VP responsiveness to pup stimuli. This activation of VP output is proposed to be the first step in the occurrence of maternal responses to pup stimuli. It is as if the stimuli are passed on to other brain regions, which then respond in an appropriate and adaptive manner. Additional support for this model is that (a) the NA and VP receive excitatory glutamatergic inputs from the PFC and from the amygdala (Brog, Salyapoongse, Deutch, & Zahm, 1993; Fuller, Russchen, & Price, 1987; Maslowski-Cobuzzi & Napier, 1994; Petrovich, Risold, & Swanson, 1996; Sesack, Deutch, Roth, & Bunney, 1989; Wright & Groenewegen, 1995; Zaborszky, Gaykema, Swanson, & Cullinan, 1997) , (b) DA action on D1 receptors in NA inhibits excitatory inputs carried by the PFC and by the amygdala (Charara & Grace, 2003; Maeda et al., 2004; Pennartz, Dolleman-Van Der Weel, Kitai, & Lopes Da Silva, 1992) , and (c) D1 receptors are located on NAs neurons that project to VP (Lu, Ghasemzadeh, & Kalivas, 1998; Robertson & Jian, 1995) .
If the model we have presented is accurate, how can it explain the occurrence of MPOA-regulated fos-positive neurons in NAs during maternal behavior (Stack et al., 2002) , as fos expression is usually considered a measure of neural activation rather than neural inhibition? One possibility is that fos is expressed in inhibitory interneurons that depress the output of NA projection neurons (Koos & Tepper, 1999; Trevitt, Morrow, & Marshall, 2005) . Another possibility is that the medium spiny NA projection neurons become momentarily active (with increased fos expression) as a result of DA and glutamate convergence, but this convergence subsequently causes the production of a retrograde inhibitory signal that functions to depress further glutamatergic activation of the NA projection system that was the target of the convergence (Harvey & Lacey, 1997) . Future work will be aimed at answering this important question.
In a recent study, Li and Fleming (2003) presented data that appear to be in disagreement with the model shown in Figure 7 and with the data of Numan et al. (2005) . They found that NAs lesions disrupted retrieval behavior in postpartum rats. This data would appear to indicate that the output of NA is critical for maternal behavior. It is interesting, however, to compare their results with the effects of D1 antagonism of NAs. Li and Fleming reported that NAs lesions increased retrieval latencies. Whereas control females retrieved all their pups to the nest in about 2 min, the NAs-lesioned females took about 10 min. This deficit is very mild and should be contrasted with the deficits observed in the present study after injections of SCH 23390 into NAs. Our females took up to an hour or more to complete retrieval. In our study, the SCH 23390 females tended to retrieve some pups and then ignore the rest while engaging in nursing behavior, and then they would sporadically leave the nest to retrieve additional pups. In contrast, in the Li and Fleming study, the females with the NAs lesions would retrieve some pups but then get distracted by other stimuli and would engage in rearing, sniffing, and feeding. This distraction effect slightly lengthened retrieval latencies. It is as if the NAs-lesioned females were too reactive to external stimuli, whereas the SCH 23390-treated females in our study appeared less reactive to such stimuli. Such an interpretation fits nicely with the model we have presented.
Some of our results might be explained in an attentional framework. DA activity in NA has been shown to be involved in attentional phenomena, and too much DA activity in NA disrupts focused attention, as measured by a disruption of prepulse inhibition and latent inhibition, for example (Joseph et al., 2000; Swerdlow, Geyer, & Braff, 2001 ). Such effects have been interpreted as indicating that too much DA activity in NA allows irrelevant stimuli to control behavior. In a sense, this is how Li and Fleming's (2003) rats behaved, and it would be consistent with an inhibitory role of DA in NA. One might conclude from these findings that too little DA in NA would make it difficult for an organism to shift its attention from one prepotent stimulus to another (see Van Den Bos & Cools, 2003) . Perhaps SCH 23390 action on NAs produces such an effect. After retrieving a few pups, it is difficult for a female to shift her attention away from the Neural model showing how the medial preoptic area (MPOA), ventral tegmental area (VTA), nucleus accumbens (NA), and ventral pallidum (VP) might interact to regulate maternal responsiveness. Connections ending in a bar are inhibitory, and those ending in an arrow are excitatory. In a nonmaternal female, pup stimuli, arriving over pathways from the amygdala and the prefrontal cortex, activate both NA and VP, resulting in low VP activity. In a maternal female with a hormone-primed MPOA, pup stimuli also activate the MPOA, which, in turn, stimulates VTA dopamine (DA) projections to NA. DA acting on NA D1 receptors is hypothesized to depress NA output, which results in increased VP activity, promoting proactive voluntary maternal responses. pups in the nest in order to retrieve the rest of the litter. Perhaps a function of MPOA activation of the mesolimbic DA system is to keep a female aroused long enough to complete the retrieval of all pups before she settles down to nurse. Of course, at a certain level of analysis, it is difficult to distinguish attentional deficits from behavioral reactivity deficits. It should be noted, however, that the attentional processes underlying latent inhibition do not appear to involve an interaction between NA with VP (Lawrence, Sharp, Peters, Gray, & Young, 2003) ; furthermore, prepulse inhibition, which does involve NA-VP interactions (Kretschmer & Koch, 1998) . seems to involve D2 rather than D1 DA receptors in NA (Trimble, Bell, & King, 2002) . These latter findings suggest that our data do not neatly fit with mechanistic explanations derived from the prepulse and latent inhibition literature (see also Van Den Bos & Cools, 2003) . However, with respect to the latent inhibition work, because the NA projects to regions other than the VP (Pennartz et al., 1992) , it is certainly possible that SCH 23390 injections into NA affected maternal behavior independent of VP.
